By Ann Lefert, National Alliance of State and Territorial AIDS Directors and Bill McColl, AIDS United, Co-Chairs of the Ryan White Work Group, Federal AIDS Policy Partnership
As Co-Chairs of the Ryan White Work Group, we wanted to provide you with an update on the Ryan White Program. As you know, the current authorization ends on September 30, 2013. However, there is no “sunset” provision in the legislation. Therefore even if Congress does not take action, the Ryan White Program will remain a part of the law allowing funding to continue to be appropriated through the annual congressional appropriations process. Continue reading
FOR IMMEDIATE RELEASE
Contact: Meico Whitlock
August 26, 2013, Washington, DC – The ADAP Crisis Task Force (ACTF) has reached a new pricing agreement with ViiV Healthcare for AIDS Drug Assistance Programs (ADAPs) for Tivicay® (dolutegravir) for the treatment of HIV-1 infected individuals. The agreed-upon ADAP direct purchase price for Tivicay®, negotiated between the ACTF and ViiV, is substantially lower than the wholesale acquisition cost (WAC), reflecting voluntary discounts that are also significantly below the mandated 340B pricing of the medication.
http://www.coachoutletsonlinestore-usa.us coach handbags wholesale
FOR IMMEDIATE RELEASE
Contact: Murray Penner
July 29, 2013, Washington, DC – As part of ongoing efforts by the ADAP Crisis Task Force (Task Force) and the pharmaceutical industry to address the continued need for access to HIV antiretroviral medicines through AIDS Drug Assistance Programs (ADAPs), the Task Force announced today that it has reached agreement with AbbVie, Gilead Sciences, Merck, and ViiV Healthcare to extend the voluntary discounts/rebates and price freezes available to all state ADAPs through December 31, 2014.
By Meico Whitlock, Senior Manager, Communications, NASTAD
In May at our 22nd Annual Meeting of state health department HIV and hepatitis program leaders in Washington, D.C., we had an opportunity to hear from federal and state leaders about Affordable Care Act (ACA) Implementation and its impact on HIV/AIDS and viral hepatitis program providers. Below is an interview with Amy Killelea, Senior Manager, Health Care Access at NASTAD and Maria Courogen, Director of Infectious Disease and Reproductive Health at the Washington State Department of Health who shared their highlights of the discussion. Continue reading